Pipeline Development Outlook and Future Implications of Unbranded Biologics and Biosimilars
With his closing thoughts, Kareem Karara looks to the potential pipeline biologic development of biosimilars and unbranded biologics.
EP: 1.Overview and Prevalence of Biologics
EP: 2.Defining Unbranded Biologics
EP: 3.Clinical Impacts of Biologics on Patient Quality of Care
EP: 4.Pipeline Development and Future Implications of Unbranded Biologics
EP: 5.Emphasizing Biologics Space as Payer Priority
EP: 6.Evolving Complexity of Biologics Space
EP: 7.Differentiating Between Unbranded Biologics and Biosimilars
EP: 8.The Impact of Unbranded Biologics in the Evolving Treatment Landscape of Autoimmune Disease
EP: 9.Implications of Multiple Switching with Biologic Therapies
EP: 10.Factors Affecting Biologics Affordability for Patient Treatment
EP: 11.Pipeline Development Outlook and Future Implications of Unbranded Biologics and Biosimilars
Kareem Karara, PharmD, BCPS, CCHP: As far as unbranded biologics that may be targeted for pipeline development in the near future, I’d love to see expanded options in the autoimmune and oncology disease spaces. These are 2 areas that are commonly managed with a range of biologic therapies and biosimilars, and they continue to be areas where we see growth of biologic management in terms of how we manage these diseases.
Regarding the future implications of unbranded biologics and biosimilars, I’m excited to see what’s to come. It’s important to see increased competition in the market for biologic drugs, which ultimately will improve patient access to these clinically important therapies and the role they have in managing chronic disease.
Transcript edited for clarity.
FDA Drafts Rules for Fair Biosimilar Promotion
June 11th 2024An updated draft guidance says that promotional materials that suggest a biosimilar or reference product is superior “are likely to be false or misleading.” The agency has also warned against making comparisons between biosimilars and those with the interchangeable designation.
Read More
